Insider filing · SMMT

Robert W Duggan bought $1.5M of Summit Therapeutics (SMMT)

Executed Jun 4, disclosed Jun 4, the same day.

Over the 21 trading sessions from the disclosed entry session (Jun 4), the stock returned +6.7% (delay-adjusted); from the execution session (Jun 4), +6.7%. Derived: entry at the session's open, exit at the close 20 sessions later.

RD Robert W Duggan Director profile →

Robert W Duggan (Director) filed 5 Form 4 reports in the trailing twelve months (5 purchases, 0 sales, 1 filed past the two-business-day deadline), most often in PLSE. Across 4 priced purchase filings, the average 21-session return was +10.9% from execution and +11.5% from disclosure (delay-adjusted; derived). The largest single filing was $50.0M of SMMT (3,810,000 sh × $13.12, as filed), executed Jun 12.

SMMT Summit Therapeutics Inc. SMMT · Healthcare · 10 filings in 24 months ticker →

Healthcare · Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, care…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→